Back to School Savings: Save up to 30% on print books and eBooks. No promo code needed.

Back to School Savings: Save up to 30%

Adoptive Cell Transfer

1st Edition - July 5, 2022

Editors: Fernando Aranda Vega, Pedro Berraondo, Lorenzo Galluzzi

Hardback ISBN:

9 7 8 - 0 - 3 2 3 - 9 9 3 9 9 - 9

eBook ISBN:

9 7 8 - 0 - 3 2 3 - 9 9 4 0 7 - 1

Adoptive Cell Transfer, Volume 370 in the International Review of Cell and Molecular Biology series highlights advances in the field, with this new volume presenting interesting… Read more

Purchase Options

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Adoptive Cell Transfer, Volume 370 in the International Review of Cell and Molecular Biology series highlights advances in the field, with this new volume presenting interesting chapters written by an international board of authors who expound on topics such as the Impact of tumor microenvironment on Adoptive Cell Transfer activity, Dendritic Cell Transfer, CAR-T Cell dysfunction and exhaustion, NK Cell-based cancer immunotherapy, Enabling CAR-T cells for solid tumors: rage against the suppressive tumor microenvironment, Improving Adoptive T-Cell therapy with cytokines administration, and What will (and should) be improved in Immunotherapy with CAR?

Cover image
Title Page
Table of Contents
Copyright
Contributors
Chapter One: Impact of tumor microenvironment on adoptive T cell transfer activity
Abstract
1: Introduction
2: T cell homing
3: Physical barriers and the extracellular matrix
4: Tumor infiltrating immunosuppressor cells
5: Metabolic competition and interstitial fluid
6: Concluding remarks
Acknowledgments
References
Chapter Two: Dendritic cell transfer for cancer immunotherapy
Abstract
1: Introduction
2: Morphological and functional characteristics of DC
3: Role of DCs in cancer immunotherapy
4: Concept of DC-based immunotherapies
5: Experimental and clinical approaches to improve DC-based immunotherapies
6: Engineering dendritic cells to improve DC-based cancer immunotherapy
7: Concluding remarks
References
Chapter Three: Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment
Abstract
1: Introduction
2: Immunomodulatory strategies
3: NK-based cellular therapy
4: NK immune cell engagers
5: Oncolytic virotherapy
6: Conclusions
References
Chapter Four: Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment
Abstract
1: Introduction
2: CAR-T cells targeting the tumor vasculature
3: CAR-T cells targeting cancer-associated fibroblasts
4: CAR-T cells targeting tumor associated macrophages and myeloid suppressor cells
5: Concluding remarks
Acknowledgments
References
Chapter Five: What will (and should) be improved in CAR immunotherapy?
Abstract
1: General concepts
2: Detection of Targets: Specificity and Affinity
3: Global molecular structure: From signaling to combination
4: Gene transfer protocols: Vectors, gene editing and upper CAR generation
5: Cell involvement: Allogenic, autologous and cell populations
6: Clinical protocols for personalized use of the product
7: Combination of therapies and procedures
8: Regulatory improvements
9: Pharma and Academic collaboration for supplying sustainable options to the health systems
10: Final discussion and conclusion
Acknowledgments
References
Chapter Six: Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy
Abstract
1: Introduction
2: History of TILs
3: Clinical studies
4: TIL manufacture
5: Antigen-specificity of TILs
6: T-cell differentiation state of TILs
7: Combinatorial therapies
8: Synthetic TILs in cancer therapy
9: Perspectives and conclusions
References

Fernando Aranda Vega

Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I” by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.

Affiliations and expertise

Fernando Aranda Vega, CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, Spain

Pedro Berraondo

Pedro Berraondo graduated in Pharmacy at the University of Navarra in 1999. In 2004 he obtained the Ph.D. at the same university. Next, he worked at the Pasteur Institute in Paris (France) under the supervision of Dr. Claude Leclerc, where he developed novel strategies in tumor immunotherapy within the European THERAVAC project. In February 2007, he joined the Immunology and Immunotherapy Program at the Cima Universidad de Navarra, where he leads the Cytokine-based Immunotherapy laboratory. He is co-inventor of ten patents and he is co-author of more than 140 publications, including publications in Nature, Nature Medicine, Nature Reviews Drug Discovery, Immunity, Cancer Discovery, and Cancer Cell. He was certified as a full professor in 2021 by AQU. He is co-director of the degree of expert in immunooncology at the Faculty of Medicine of the University of Navarra, and is in charge of the undergraduate course of macromolecular structure at the Faculty of Sciences of the University of Navarra. He is also the coordinator of the immuno-oncology work module at CIBERONC.

Affiliations and expertise

CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, Spain

Lorenzo Galluzzi

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.

Affiliations and expertise

Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA